# TOPACIO (niraparib): what clinicians are saying

> 183 statements from 35 sources (3 podcasts, 3 videos, 24 posts, 3 papers, 2 registry records), 28 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026.

## Report

- Trial: Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
- NCT ID: NCT02657889
- Registry: https://clinicaltrials.gov/study/NCT02657889
- Sponsor: Tesaro, Inc.
- Phase: Phase 1/Phase 2
- Status: Completed
- Drugs tested: niraparib plus pembrolizumab
- Indication: advanced triple-negative breast cancer or recurrent ovarian cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-15 UTC
- Last checked: 2026-11-15 UTC
- Release hash: eea71a38121b4281d3ed59a1393baff4f50037099b6329691ef4760e1de6290b

## Counts

- Commentary sources screened: 69
- Sources cited by verified statements: 35
- Verified statements: 183
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 28
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 18
- Speakers cited: 18
- Cited speakers with a verified identity: 9
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 6
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 6
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Medical oncology
  - 2 physician, Surgical oncology
  - 1 physician, specialty not confirmed
  - 1 physician, Gynecologic oncology
- Organisational or shared accounts (not counted as people): 7

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A surgical oncologist reads TOPACIO as suggesting the drugs work better together, citing BRCA-wild-type ovarian responses. Another speaker finds the drugs’ contributions difficult to separate in TNBC; a speaker described in the sources as involved in the trial sees TNBC responses as similar to PARP monotherapy. The ovarian and TNBC observations are not directly matched. Genomic and immune markers still need validation before they can guide treatment selection.

## Question clinicians left open

What do clinicians need to see in response rates and duration to determine whether niraparib plus pembrolizumab adds benefit over PARP inhibitor monotherapy in advanced triple-negative breast cancer or recurrent ovarian cancer?

From finding F1 (11 statements from 3 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Niraparib plus pembrolizumab: where speakers split on what the combination adds
  - 11 statements from 3 speakers in 5 sources, 2 of them podcasts or videos.
  - 3 of the 3 named speakers in this finding take a side on this question: 2 on one side, 1 on the other.
  - 1 of the report's 6 cited clinicians.
- F2. Niraparib plus pembrolizumab: a clinician cites activity but notes no NCCN listing
  - 11 statements from 2 speakers in 3 sources, all podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 1 of the report's 6 cited clinicians.
- F3. Activity beyond BRCA: most speakers see it, but some seek selection markers
  - 22 statements from 7 speakers in 10 sources, 3 of them podcasts or videos.
  - 6 of the 7 named speakers in this finding hold this view; 2 of the 7 hold its caveat, “some seek selection markers”.
  - 4 of the report's 6 cited clinicians.
- F4. TOPACIO response data: what speakers highlight, but one notes ORR fell
  - 24 statements from 9 speakers in 19 sources.
  - 9 of the 9 named speakers in this finding hold this view; 1 of the 9 holds its caveat, “one notes ORR fell”.
  - 2 of the report's 6 cited clinicians.
- F5. Tolerability in breast cancer: where speakers split on which patients it covers
  - 6 statements from 2 speakers in 4 sources, 1 of them a podcast or video.
  - 2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other.
  - 1 of the report's 6 cited clinicians.
- F9. PARP–immunotherapy rationale: speakers support it, but claim no clinical synergy
  - 23 statements from 2 speakers in 2 sources, all podcasts or videos.
  - 2 of the 2 named speakers in this finding hold this view; 2 of them hold its caveat, “claim no clinical synergy”.
  - 1 of the report's 6 cited clinicians.

### Beyond the trial population

- F6. Platinum resistance: how speakers weigh therapy, supportive care and when to stop
  - 24 statements from 2 speakers in 2 sources, all podcasts or videos.
  - 2 of the 2 named speakers in this finding hold this view.
  - 1 of the report's 6 cited clinicians.
- F7. Platinum resistance: why a clinician favors immunochemotherapy over PD-1 drugs alone
  - 11 statements from 1 speaker in 2 sources, all podcasts or videos.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 6 cited clinicians.
- F8. MEDIOLA triplet: a speaker favors it, but leaves its advantage open
  - 2 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view; 1 of them holds its caveat, “leave its advantage open”.
  - No named clinician · accounts and unnamed speakers.
- F10. PARP combinations: a speaker looks to biopsies, macrophages and priming
  - 30 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

4 of the 10 findings and 62 of the 183 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 11 | 10 | 5 | 3 | 3 |
| F2 | 11 | 9 | 3 | 2 | 3 |
| F3 | 22 | 19 | 10 | 7 | 3 |
| F4 | 24 | 21 | 19 | 9 | 3 |
| F5 | 6 | 6 | 4 | 2 | 3 |
| F9 | 23 | 11 | 2 | 2 | 3 |
| F6 | 24 | 10 | 2 | 2 | 5 |
| F7 | 11 | 8 | 2 | 1 | 4 |
| F8 | 2 | 1 | 1 | 1 | 3 |
| F10 | 30 | 15 | 1 | 1 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 5 | 1 | 0 | 3 | 2 | 15 | 1 | 1 post or article, 2 podcasts and video, 2 publications |
| F2 | 5 | 1 | 0 | 0 | 5 | 12 | 1 | 3 podcasts and video |
| F3 | 7 | 3 | 1 | 3 | 8 | 24 | 5 | 6 posts and articles, 3 podcasts and video, 1 publication |
| F4 | 15 | 2 | 0 | 2 | 5 | 25 | 1 | 19 posts and articles |
| F5 | 3 | 0 | 0 | 0 | 3 | 6 | 0 | 1 post or article, 1 podcast or video, 1 publication, 1 registry |
| F9 | 12 | 2 | 1 | 3 | 5 | 27 | 1 | 2 podcasts and video |
| F6 | 12 | 0 | 0 | 0 | 12 | 25 | 2 | 2 podcasts and video |
| F7 | 4 | 0 | 0 | 2 | 5 | 16 | 1 | 2 podcasts and video |
| F8 | 0 | 1 | 0 | 1 | 0 | 4 | 0 | 1 podcast or video |
| F10 | 18 | 2 | 2 | 1 | 7 | 32 | 0 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs): no finding draws on it directly
- Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1: F1 (6 shared claims), F2 (3 shared claims), F3 (4 shared claims), F4 (6 shared claims)
- Secondary endpoints: F1 (2 shared claims), F2 (1 shared claims), F4 (3 shared claims), F9 (1 shared claims)
- Population and setting: F1 (3 shared claims), F2 (2 shared claims), F3 (6 shared claims), F4 (2 shared claims), F5 (1 shared claims)
- The comparison: F1 (5 shared claims), F3 (1 shared claims), F4 (1 shared claims), F9 (1 shared claims)
- Safety and tolerability: F3 (1 shared claims), F5 (2 shared claims)
- Design and conduct: no finding draws on it directly

## Abbreviations

- DLT: dose-limiting toxicity
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- PARP: poly(ADP-ribose) polymerase
- PD-L1: programmed death-ligand 1
- RECIST: Response Evaluation Criteria in Solid Tumors

## Examples from the report

Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.

- Physician, US, identity checked against NPI · post on X · Jun 2018 (finding F3): A physician describes great activity and a good toxicity profile for niraparib plus pembrolizumab in TOPACIO TNBC, extending beyond BRCA mutation and PD-L1 expression.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 183 | Paid |
| Who said each statement: the cited speakers | 18 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 6 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 9 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 35 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 6 of the 18 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

12 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs) | no commentary found | 0 | 0 |
| Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | discussed | 16 | 9 |
| Secondary endpoints | discussed | 5 | 5 |
| Population and setting | discussed | 9 | 7 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 5 | 3 |
| Safety and tolerability | discussed | 2 | 2 |
| Design and conduct | no commentary found | 0 | 0 |
| Biomarker interpretation and candidate selection measures | discussed | 18 | 9 |
| Guideline positioning, PARP-class caution and treatment-versus-maintenance boundaries | discussed | 10 | 3 |
| Early enthusiasm, evolving ORR expectations and development caution | discussed | 22 | 18 |
| Recurrent platinum-resistant ovarian cancer treatment selection, access and supportive care | discussed | 24 | 2 |
| Alternative ovarian immunotherapy regimens and the MEDIOLA comparison | discussed | 12 | 3 |
| Biological rationale and contextual MEDIOLA, TOPACIO and OlympiAD comparisons | discussed | 23 | 2 |
| Biopsy-led research, macrophage metabolism, CSF1R modulation and STING priming | discussed | 30 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 109 statements · 60%** | | | |
| YouTube | 62 | 3 | 3 |
| Podcasts | 47 | 3 | 3 |
| **Posts · 30 statements · 16%** | | | |
| X threads | 30 | 24 | 62 |
| Bluesky threads | 0 | 0 | 1 |
| **Primary sources · 44 statements · 24%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 34 | 3 | not screened |
| Registry (primary source, cited for context) | 10 | 2 | not screened |

- Screened window: 2017-04-20 to 2026-07-21
- Cited window: 2017-04-20 to 2026-07-21
- Retrieved: 2026-11-15

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
- Registry: NCT02657889 (https://clinicaltrials.gov/study/NCT02657889)
- Study IDs: 213363 · 3000-PN162-01-001 (Tesaro)
- Sponsor: Tesaro, Inc.
- Collaborators: Merck Sharp & Dohme LLC
- Design: Phase 1/Phase 2 · interventional, na, single group, phase1, phase2
- Status: Completed
- Enrollment: 122 (actual)
- Start: 2016-04-15 (actual)
- Primary completion: 2018-05-14 (actual)
- Primary endpoint: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs) (During Cycle 1, ie, during the first 21 days of treatment)
- Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 (Up to 40 weeks)
- Intervention: niraparib (drug)
- Intervention: pembrolizumab (biological)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Not yet captured in this edition: a view on checkpoint-combination benefit–risk and exploratory patient selection in recurrent ovarian cancer; a view on checkpoint inhibitor monotherapy versus chemotherapy as context for combination treatment in recurrent ovarian cancer; a view on mirvetuximab as an alternative for platinum-resistant ovarian cancer, including patient selection, efficacy and toxicity; a view on checkpoint-inhibitor combination selection, toxicity and exploratory subgroups in recurrent ovarian cancer; a view on molecular profiling and mutation-selected trial options for recurrent platinum-resistant ovarian cancer.
- Discussion that does not name the trial may be missing from this edition.
- 2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
- 175 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 24 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion; no prevalence, consensus or adoption rate can be inferred.
- Several X accounts are organizational, anonymous or lack established clinical roles. Relays and reposts do not demonstrate independent clinical endorsement.
- Unidentified speech remains unnamed even when the recording includes named participants; it may belong to a participant already discussed.
- Commentary spans different years, cohorts, treatment settings and stages of data maturity. Differences do not by themselves demonstrate that a speaker changed position.
- Descriptions of approvals, guidance and treatment practice remain attributed to the time and source that expressed them, including the updated episode dated July 21, 2026.
- The complete 2019 TNBC and ovarian results articles were unavailable. Available article summaries and the ovarian correlative publication support only the context they contain.
- Important alternative-treatment assessments remain incomplete: mirvetuximab regimens, bevacizumab selection, checkpoint doublets, pazopanib and cytotoxic choices tailored to neuropathy or access burdens. The report is therefore not a complete treatment pathway or comparison of alternatives.
- Some connected discussion of comparator interpretation and constraints on further development is not fully characterized, limiting conclusions about why particular alternatives were favored or pursued.
- Some alternative PARP-combination discussion was incomplete or had unclear drug names and prior-PARP eligibility wording, limiting assessment of those strategies.
- The single-arm design and cross-study comparisons do not establish the combination's incremental efficacy or a treatment-predictive biomarker.
- The ovarian biomarker work is exploratory, with incomplete tissue availability and a need for independent validation; laboratory and mouse findings are not clinical treatment evidence.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-15 UTC: current edition
  - Routine maintenance: 4 fixes (names, counts, text):
    - 2026-11-15 UTC: The trial's name is spelled as its investigators write it, “TOPACIO” (NCT02657889), outside quotations (was “Topacio”, “Topazio”).
    - 2026-11-15 UTC: An editorial bracket follows a transcription-garbled trial name in quotations: “Topazio [TOPACIO]”.
    - 2026-11-15 UTC: Other trials' names are spelled as their investigators write them, outside quotations: “MEDIOLA” (was “Madiola”), “KEYLYNK” (was “KEYLINK”).
    - 2026-11-17 UTC: Corrected to match the delivered report: finding titles; the speakers each finding title counts; the limitations; the examples from the report. Finding titles on this page say which of the speakers hold each view, with no word judging benefit or harm; the report keeps its own titles.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-15 UTC. No changes.

## Offer

- Size: Standard · 183 verified statements · 28 from 6 confirmed clinicians
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $2,200
- 6 months of updates: $3,100
- 12 months of updates: $4,400
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (9 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/topacio-nct02657889
- Agents: POST https://www.erudio.com/api/orders with {"report": "topacio-nct02657889", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=topacio-nct02657889

## Cite

Erudio Health. TOPACIO (NCT02657889): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 15, 2026. https://www.erudio.com/reports/topacio-nct02657889

## Questions

### How much does the TOPACIO report cost?

One edition costs $1,250 (Standard · 183 verified statements · 28 from 6 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the TOPACIO report cover?

183 statements from 35 sources (3 podcasts, 3 videos, 24 posts, 3 papers, 2 registry records), 28 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the TOPACIO report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "topacio-nct02657889" }) previews it and create_order({ "report": "topacio-nct02657889", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the TOPACIO report?

Edition 1 (version 1.0.0), accepted Nov 15, 2026 UTC; last checked for new commentary Nov 15, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/topacio-nct02657889.json
- Markdown: https://www.erudio.com/reports/topacio-nct02657889.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/topacio-nct02657889/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "topacio-nct02657889"}`
